BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang ZY, Ding XQ, Zhu H, Wang RX, Pan XR, Tong JH. KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. Front Oncol 2019;9:1295. [PMID: 31850201 DOI: 10.3389/fonc.2019.01295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Abdallah R, Taly V, Zhao S, Pietrasz D, Bachet JB, Basile D, Mas L, Zaanan A, Laurent-Puig P, Taieb J. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treat Rev 2020;87:102028. [PMID: 32485509 DOI: 10.1016/j.ctrv.2020.102028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Olmedillas-López S, Olivera-Salazar R, García-Arranz M, García-Olmo D. Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review. Mol Diagn Ther 2021. [PMID: 34773243 DOI: 10.1007/s40291-021-00562-2] [Reference Citation Analysis]
3 Manoharan A, Sambandam R, Bhat V. Recent technologies enhancing the clinical utility of circulating tumor DNA. Clin Chim Acta 2020;510:498-506. [PMID: 32795543 DOI: 10.1016/j.cca.2020.08.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Chen J, Yao D, Chen W, Li Z, Guo Y, Zhu F, Hu X. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer. Int J Biol Markers 2022;:17246008211070018. [PMID: 35001683 DOI: 10.1177/17246008211070018] [Reference Citation Analysis]
6 Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent-Puig P, Zaanan A. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers (Basel) 2021;13:4743. [PMID: 34638228 DOI: 10.3390/cancers13194743] [Reference Citation Analysis]
7 To YH, Lee B, Wong HL, Gibbs P, Tie J. Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. Visc Med 2020;36:388-96. [PMID: 33178736 DOI: 10.1159/000509657] [Reference Citation Analysis]
8 Patel N, Petrinic T, Silva M, Soonawalla Z, Reddy S, Gordon-Weeks A. The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32825312 DOI: 10.3390/cancers12092353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Toledano-Fonseca M, Cano MT, Inga E, Rodríguez-Alonso R, Gómez-España MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodríguez JR, Rodríguez-Ariza A, Aranda E. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Cancers (Basel) 2020;12:E1754. [PMID: 32630266 DOI: 10.3390/cancers12071754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang ZY, Wang RX, Ding XQ, Zhang X, Pan XR, Tong JH. A Protocol for Cancer-Related Mutation Detection on Exosomal DNA in Clinical Application. Front Oncol 2020;10:558106. [PMID: 33042841 DOI: 10.3389/fonc.2020.558106] [Reference Citation Analysis]
12 Woo SM, Kim MK, Park B, Cho EH, Lee TR, Ki CS, Yoon KA, Kim YH, Choi W, Kim DY, Hwang JH, Cho JH, Han SS, Lee WJ, Park SJ, Kong SY. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Cancers (Basel) 2021;13:5466. [PMID: 34771630 DOI: 10.3390/cancers13215466] [Reference Citation Analysis]
13 Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Pancreatology. 2021;21:363-378. [PMID: 33451936 DOI: 10.1016/j.pan.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Balendran-Braun S, Kieler M, Liebmann-Reindl S, Unseld M, Bianconi D, W Prager G, Streubel B. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Cancer Manag Res 2021;13:6249-61. [PMID: 34393517 DOI: 10.2147/CMAR.S308029] [Reference Citation Analysis]
15 Xu Z, Peng M, Zhang Z, Zeng H, Shi R, Ma X, Wang L, Liao B. Graphene-Assisted Electrochemical Sensor for Detection of Pancreatic Cancer Markers. Front Chem 2021;9:733371. [PMID: 34490213 DOI: 10.3389/fchem.2021.733371] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]